Dereci A, et al. – In this meta-analysis, researchers summarized reports on clinical outcomes of implantable cardioverter-defibrillator (ICD) therapy in patients with Brugada syndrome. They searched the MEDLINE database and identified 828 relevant studies reporting outcome and complications after ICD therapy in patients with Brugada syndrome. Of these studies, 22—representing 1,539 patients (mean age 45 years, 18% women) followed for mean of 4.9 years—met inclusion criteria. According to findings, ICD therapy may benefit patients with Brugada syndrome at high risk for ventricular arrhythmia. An appropriate ICD intervention rate of 3.1 per 100 person-years and low cardiac and noncardiac mortality rates were noted in relation to ICD therapy. In addition, considerable morbidity may be seen due to inappropriate ICD interventions and ICD-related complications.